医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

China’s Lianhua Qingwen Capsules Offers an Herbal Therapeutic Solution for the Pandemic

2020年12月17日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

Lianhua Qingwen Capsules is a traditional Chinese patent medicine produced by Yiling Pharmaceutical of China. Holding fast to the original aspiration of a pharmaceutical enterprise, Yiling Pharmaceutical has actively participated in China’s fight against Covid-19 as well as to the world’s fight.

Clinical researches have shown that Lianhua Qingwen can effectively inhibit the Novel Coronavirus, and is widely used in the treatment of patients with mild and moderate symptoms. A research team led by Mr. Zhong Nanshan, member of China Academy of Engeering, published a paper named Lianhua Qingwen Exerts Anti-Viral and Anti-inflammatory Activity against Novel Coronavirus (SARS-CoV-2) in Pharmacological Research, a leading journal on pharmacology. The research has explained the pharmacological basis of the exact efficacy of Lianhua Qingwen in COVID-19 treatment.

What’s more, a research directed by Academician Zhong Nanshan, Li Lanjuan and Zhang Boli and done in more than 20 hospitals that received COVID-19 patients has resulted in a paper published in Phytomedicine, an international leading journal, has indicated that Lianhua Qingwen can obviously increase the improvement rate of the clinical symptoms caused by COVID-19 such as fever, fatigue and cough; it can also obviously improve the pulmonary imaging lesions, shortens the duration of symptoms and increase the clinical curative rate.

In Diagnosis and Treatment Protocol for COVID-19 (version 4-version 8) published by China’s National Health Commission and National Administration of Traditional Chinese Medicine, Lianhua Qingwen has been recommended in prevention and treatment of fatigue and fever in medical observation period. In China’s fight against COVID-19, it was the most widely used drug in hospitals.

In view of the outstanding performance of Lianhua Qingwen, media have been very optimistic about the prospect of Lianhua Qingwen and have expected that it will offer an herbal therapeutic solution for the pandemic.

Lianhua Qingwen has been launched in the Philippines on November 23. Now it’s avaible in Mercury Drug, Southstar Drug and Watson.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005396/en/

CONTACT

First Name: Li

Last Name: Kristy

E-mail:kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates